Myriad Genetics, Inc.
MYGN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$569.27M
Close$
$-1.99
133.1% downside
Current Fair Value
133.1% downsideOvervalued by 133.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $569.27 Million |
|---|---|
| Enterprise Value | $664.57 Million |
| Earnings per Share | $-3.96 |
| Beta | 1.64 |
| Outstanding Shares | 94,800,000 |
Return
| Return on Equity | -37.05% |
|---|---|
| Return on Assets | -17.62% |
| Return on Invested Capital | -18.85% |
Valuation & Multiples
| P/E Ratio | -5.32 |
|---|---|
| PEG | 6.11 |
| Price to Sales | 0.75 |
| Price to Book Ratio | 2.0 |
| Enterprise Value to Revenue | 0.82 |
| Enterprise Value to EBIT | -6.94 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.32 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-0.20
Consensus analyst estimateRevenue Estimate
$191.33 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 2, 2027
EPS Estimate
$-0.18
Consensus analyst estimateRevenue Estimate
$196.11 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 48.36% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.26%▼ 95.52% |
|---|---|
| Total Invested | $1.07M▼ 99.79% |
| Investors Holding | 12▼ 189.00% |
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...